GlassScriptPhysician profile
Jeffrey N Cofie
NPI 1205316296
$92,815.17
in general payments reported to CMS, 2019-2025
22 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $347 · 2021: $2,006 · 2022: $1,830 · 2023: $4,119 · 2024: $26K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Travel and Lodging: $17K · Food and Beverage: $10K · Consulting Fee: $6,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,100.00 |
| Travel and Lodging | $17,200.49 |
| Food and Beverage | $10,465.97 |
| Consulting Fee | $6,475.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $81,918.32 | 2021-2025 | Acuvue, Tecnis Simplicity |
| Alcon Vision LLC | $2,973.71 | 2022-2025 | Total30, Tryptyr, Rhopressa |
| Bausch & Lomb Americas INC. | $1,998.64 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $864.15 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $683.13 | 2024-2025 | Vevye, Triesence |
| Sun Pharmaceutical Industries INC. | $602.77 | 2021-2024 | |
| Glaukos Corporation | $544.86 | 2024-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Radius |
| Biotissue Holdings INC. | $388.16 | 2024-2025 | |
| Dompe US, INC. | $369.74 | 2024-2025 | Oxervate |
| Coopervision INC. | $345.29 | 2021-2023 | Biofinity Contact Lens, Myday Contact Lens |
| Sight Sciences, INC. | $276.30 | 2022-2024 | Tearcare System, Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $255.79 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $244.57 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $239.66 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $234.15 | 2024 | Syfovre |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $177.63 | 2019-2021 | |
| Allergan, INC. | $168.42 | 2019 | |
| Horizon Therapeutics Plc | $147.99 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $144.20 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $120.55 | 2019-2020 | |
| Abbvie INC. | $95.25 | 2022 | |
| Oyster Point Pharma, INC. | $21.89 | 2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cofie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.